/PRNewswire/ — RnRMarketResearch.com offers 2015 Valsartan (CAS 137862-53-4) Industry Report Global and Chinese Market Scenario, Valsartan Comprehensive patent search and Valsartan Patent, Extension and Data Exclusivity Expiry Snapshot (51 ... Prbox.com, 1 day ago
Valsartan Market (CAS 137862-53-4) 2020 Forecasts and Patent Search, Valsartan Patent Extension and Data Exclusivity Expiry Snapshot for 51 Countries in New Research Reports - Reliance Trust, 1 day ago
GBI Research, the leading business intelligence provider, has released its latest research, "Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries", ...Bloomberg, 1 month ago Antihypertensive Therapeutics Market Trends, Growth and Forecast up to 2020 Individual.com, 1 month ago
Designs on you: Effective package design is proven to deliver tangible results and adherence gains, translating into improved health outcomes for patients With recent governmental reforms in healthcare across the US, Europe, and extending into ...European Pharmaceutical Manufacturer, 1 month ago
Slumping sales for cardiovascular drugs isn't exactly a new phenomenon for Big Pharma, with some of the industry's top drugmakers suffering from recent patent expirations. But a new report shows which CV franchises have been hurt the most. ...FiercePharma, 1 month ago
The hypothyroid drug levothyroxine ( Synthroid , AbbVie) was the most prescribed drug in the United States, and the arthritis drug adalimumab ( Humira , Abbott Laboratories) was the best-selling drug through March of this year, according to recent ...Dermatology Online Journal, 1 month ago
CMS spent $2.5 billion on the heartburn drug in 2013 on 8.2 million claims. Henry Powderly, Managing Editor The Center for Medicare and Medicaid Services spent more than $103 billion on prescription drugs in 2013 under the Medicare Part D ...Healthcare Finance News, 2 months ago
on your WebpageAdd Widget >Get your members hooked!